ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK, said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting ...